Corrigendum: Pattern recognition receptors: Immune targets to enhance cancer immunotherapy (Annals of Oncology (2017) 28:8 (1756-1766) DOI: 10.1093/annonc/mdx179);Pattern recognition receptors: Immune targets to enhance cancer immunotherapy

Annals of Oncology

Volumn 28, Issue 8, 2017, Pages 1756-1766

  Shekarian, T ^a,b   Valsesia Wittmann, S ^c   Brody, J ^b   Michallet, M C ^a   Depil, S ^a,b   Caux, C ^a,b   Marabelle, Aurélien ^d,e  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e University Paris XI   (France)

Author keywords

Cancer; Immune checkpoints; Immunotherapy; Pattern recognition receptors

Indexed keywords

ANTINEOPLASTIC AGENT; C TYPE LECTIN RECEPTOR; DNA; GAMMA INTERFERON; LECTIN RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PATTERN RECOGNITION RECEPTOR AGONIST; RIG I LIKE RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; APOPTOSIS; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; INFECTIOUS AGENT; LYMPHOCYTE COUNT; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY; AGONISTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, PATTERN RECOGNITION;

EID: 85029333573     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdz225     Document Type: Erratum

References (86)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489
2. Chen DS, Mellman I. Oncology meets immunology: the cancerimmunity cycle. Immunity 2013; 39: 1-10
3. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820
4. Termeer C, Benedix F, Sleeman J, Et A. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195: 99-111
5. Llanos C, Mackern-Oberti JP, Vega F et al. Tolerogenic dendritic cells as a therapy for treating lupus. Clin Immunol 2013; 148: 237-245
6. Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E. Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 2010; 6: 704-714
7. Husebye H, Halaas O, Stenmark H et al. Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. Embo J 2006; 25: 683-692
8. Hennessy EJ, Parker AE, O'Neill LAJ. Targeting Toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov 2010; 9: 293-307
9. Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol 2013; 93: 847-863
10. Werling D, Jann OC, Offord V et al. Variation matters: TLR structure and species-specific pathogen recognition. Trends Immunol 2009; 30: 124-130
11. Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol 2012; 10: 103-106
12. Cottalorda A, Mercier BC, Mbitikon-Kobo FM et al. TLR2 engagement on memory CD8(+) T cells improves their cytokine-mediated proliferation and IFN-gamma secretion in the absence of Ag. Eur J Immunol 2009; 39: 2673-2681
13. Sutmuller RPM, den Brok MHMGM, Kramer M et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006; 116: 485-494
14. Caramalho I, Lopes-Carvalho T, Ostler D et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197: 403-411
15. Huang B, Zhao J, Unkeless JC et al. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008; 27: 218-224
16. Menendez D, Shatz M, Azzam K et al. The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet 2011; 7: e1001360
17. Brignole C, Marimpietri D, Di Paolo D et al. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res 2010; 70: 9816-9826
18. Li J, Song W, Czerwinski DKK et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007; 179: 2493-2500
19. Rayburn ER, Wang W, Zhang Z et al. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 2006; 66: 1653-1663
20. Salaun B, Coste I, Rissoan M et al. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006; 176: 4894-4901
21. Sato Y, Goto Y, Narita N, Hoon DSB. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron 2009; 2(Suppl 1): 205-214
22. Yang H, Wang B, Wang T et al. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS One 2014; 9: e109980
23. Mäkinen LK, Atula T, Häyry V et al. Predictive role of toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma. Oral Oncol 2014; doi:10.1016/j.oral oncology 2015; 51: 96-102
24. Chatterjee S, Cremer I. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung. Cancer Cancer Res 2013; 73: 4629-4640
25. Ignatz-Hoover JJ, Wang H, Moreton SA et al. The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia 2015; 29: 918-926
26. Pradere J-P, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene 2014; 33: 3485-3495
27. Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28: 4324-4332
28. Kim YH, Gratzinger D, Harrison C et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012; 119: 355-363
29. Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174: 1259-1268
30. Singh M, Khong H, Dai Z et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol 2014; 193: 4722-4731
31. Glavan TM, Pavelic J. The exploitation of Toll-like receptor 3 signaling in cancer therapy. Curr Pharm Des 2014; 20: 6555-6564
32. Salaun B, Zitvogel L, Asselin-Paturel C et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res 2011; 71: 1607-1614
33. Loo Y-M, Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011; 34: 680-692
34. van den Boorn JG, Hartmann G, van den Boorn JG. Turning tumors into vaccines: co-opting the innate immune system. Immunity 2013; 39: 27-37
35. Jiang L-J, Zhang N-N, Ding F et al. RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation. Proc Natl Acad Sci USA 2011; 108: 1897-1902
36. Ellermeier J, Wei J, Duewell P et al. Therapeutic efficacy of bifunctional siRNA combining TGF-b1 silencing with RIG-I activation in pancreatic cancer. Cancer Res 2013; 73: 1709-1720
37. Besch R, Poeck H, Hohenauer T et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 2009; 119: 2399-2411
38. Tormo D, Chȩcińska A, Alonso-Curbelo D et al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 2009; 16: 103-114
39. Goubau D, Deddouche S, Reis E Sousa C. Cytosolic sensing of viruses. Immunity 2013; 38: 855-869
40. Kübler K, Gehrke N, Riemann S et al. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res 2010; 70: 5293-5304
41. Kübler K, tho Pesch C, Gehrke N et al. Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. Eur J Immunol 2011; 41: 3028-3039
42. Inao T, Harashima N, Monma H et al. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer. Breast Cancer Res Treat 2012; 134: 89-100
43. Bhoopathi P, Quinn BA, Gui Q et al. Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid. Cancer Res 2014; 74: 6224-6235
44. Saleh M. The machinery of Nod-like receptors: refining the paths to immunity and cell death. Immunol Rev 2011; 243: 235-246
45. Allen IC, Wilson JE, SchneiderMet al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-jB signaling. Immunity 2012; 36: 742-754
46. Kufer TA, Sansonetti PJ. NLR functions beyond pathogen recognition. Nat Immunol 2011; 12: 121-128
47. Eisenbarth SC, Williams A, Colegio OR et al. NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 2012; 484: 510-513
48. Ghiringhelli F, Apetoh L, Tesniere A et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178
49. Frampton JE. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs 2010; 12: 141-153
50. Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006; 24: 93-103
51. Ishii KJ, Coban C, Kato H et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006; 7: 40-48
52. Chiu Y-H, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009; 138: 576-591
53. Hornung V, Latz E. Intracellular DNA recognition. Nat Rev Immunol 2010; 10: 123-130
54. Lee J, Li L, Gretz N et al. Absent in melanoma 2 (AIM2) is an important mediator of interferon-dependent and-independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. Oncogene 2012; 31: 1242-1253
55. Patsos G, Germann A, Gebert J, Dihlmann S. Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer 2010; 126: 1838-1849
56. Ponomareva L, Liu H, Duan X et al. AIM2, an interferon-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. Mol Cancer Res 2013; 11: 1193-1202
57. Lladser A, Mougiakakos D, Tufvesson H et al. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther 2011; 19: 594-601
58. Sun L, Wu J, Du F, Chen XCZ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013; 339(6121): 786-791
59. Tang EDWC. Single amino acid change in STING leads to constitutive active signaling. PLoS One 2015; 10(3): e0120090
60. Woo SR, Fuertes MB, Corrales L et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41: 830-842
61. Corrales L, Glickman LH, McWhirter SM et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015; 11: 1018-1030
62. Chandra DGC. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res 2014; 2(9): 901-910
63. Kingeter LM, Lin X. C-type lectin receptor-induced NF-jB activation in innate immune and inflammatory responses. Cell Mol Immunol 2012; 9: 105-112
64. Tel J. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur J Immunol 2011; 41(4): 1014-1023
65. Plato A, Hardison SEBG. Pattern recognition receptors in antifungal immunity. Semin Immunopathol 2015; 37(2): 97-106
66. Weis WI, Drickamer KHW. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 1992; 360(6400): 127-134. n.d
67. Masuda Y, Inoue H, Ohta H et al. Oral administration of soluble b-glucans extracted from Grifola frondosa induces systemic antitumor immune response and decreases immunosuppression in tumor-bearing mice. Int J Cancer 2013; 133: 108-119
68. Yamasaki S, Ishikawa E, Sakuma M et al. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat Immunol 2008; 9: 1179-1188
69. Zhang J-G, Czabotar PE, Policheni AN et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity 2012; 36: 646-657
70. Lu S, Bevier M, Huhn S et al. Genetic variants in C-type lectin genes are associated with colorectal cancer susceptibility and clinical outcome. Int J Cancer 2013; 133: 2325-2333
71. Chan AS, Jonas AB, Qiu X, Ottoson NR, Walsh RM, Gorden KB et al. Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation. PLoS One 2016; 11: e0165909
72. Schneller F, Engel-Riedel W, Thomas M, Kollmeier J, Sadjadian P, Wolf M et al. Safety of imprime PGG, a novel innate immune cell modulator, in adults with stage IV non-small cell lung cancer: an integrated analysis of two randomized phase 2 studies. J Clin Oncol 2015; 33(Suppl): abstr 3071
73. Marabelle A, Kohrt H, Sagiv-Barfi I et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013; 123: 2447-2463
74. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59: 5429-5432
75. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009; 113: 3546-3552
76. Varghese B, Widman A, Do J et al. Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood 2009; 114: 4477-4485
77. Sagiv-Barfi I, Kohrt HE, Burckhardt L et al. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in syngeneic mouse lymphoma model. Blood 2015; 125: 2079-2086
78. Fu J, Kanne DB, Leong M et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med 2015; 7: 283ra52
79. Marabelle A, Kohrt HE, Caux C, Levy R. Intra-tumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014; 20: 1747-1756
80. Andtbacka RHI, Kaufman HL, Collichio F et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33: 2780-2788
81. Andtbacka RHI, Ross M, Puzanov I et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol 2016; 23: 4169-4177
82. Kim MK, Breitbach CJ, Moon A et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med 2013; 5: 185ra63
83. Heo J, Reid T, Ruo L et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19: 329-336
84. Long GV, Dummer R, Ribas A, Puzanov I, VanderWalde A, Andtbacka RHI et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. ASCO Meet Abstr 2016; 34: 9568
85. Puzanov I, Milhem MM, Minor D et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 2016; 34: 2619-2626
86. Galluzzi L, Buqué A, Kepp O et al. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017; 17: 97-111